Improving quality in prostate cancer care through personalised diagnostic testing – Educational project 2025/2026

 

Background

Personalised diagnostic tests are used to tailor strategies for patient-specific disease detection, treatment, or prevention. Molecular unique features of each patient and his tumour (i.e. gene alterations, protein expression levels) could act as indicators for treatment selection or disease prognosis, with significant potential impact on the quality of life as well.

Applications of germline/somatic molecular testing and biochemical markers have become a critical component of prostate cancer care. Indeed, they are now used for risk assessment, choice of treatment, prognosis and disease follow up. In addition, molecular imaging and pharmacogenomic tests could offer further advantages, to achieve a more comprehensive knowledge of the disease.

To ensure that all men benefit from those strategies, personalised medicine should be validated in different cohorts of prostate cancer patients, in order to guarantee equitable access to all of them.

 

Format

Given the significance of enhancing the quality of prostate cancer care through personalised diagnostic testing, Sharing Progress in Cancer Care is carrying out a targeted project which foresees two stages:

• A closed in-person task force, which will be held on 12^th June 2025
• A manuscript summarising the most important outcomes of the task force

 

Faculty

Chairs
Anders Bjartell, Lund University, Skåne University Hospital, Malmö, SE
Hendrik Van Poppel, EAU Policy Office Chairman, KU Leuven, BE

Experts
Bernardo Bonanni, European Institute of Oncology, Milan, IT
Alberto Bossi, Gustave Roussy Cancer Institute, Villejuif, FR
Erik Briers, ESR Patient Advisory Group and Europa Uomo, Antwerp, BE
Eva Compérat, Medical University Vienna, AT
Ken Herrmann, Universitätsklinikum Essen, DE
Jan Oldenburg, Akershus University Hospital, Nordbyhagen, NO

 

Task Force programme

1. Objects and deliverable of the task force – Anders Bjartell, SE
2. Molecular pathology latest advancements in personalized prostate cancer treatments – Eva Compérat, AT
3. Personalised diagnostic testing. The urologist’s view – Anders Bjartell, SE
4. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer – Bernardo Bonanni, IT
5. Treatment approaches, genomics, and equitable access to advancing prostate cancer care – Jan Oldenburg, NO
6. Overview of the state of the art of PSMA theranostics in mCRPC and mCSPC – Ken Herrmann, DE
7. Optimization of mCRPC and mCSPC treatment selections – Alberto Bossi, FR
8. Personalised prostate cancer care: perspectives and the role of prostate cancer patient organisations – Erik Briers, BE

 

Auspices

This educational project will be held under the auspices of the European Association of Urology.

Acknowledgment

This educational project is developed in collaboration with Pfizer.

 

Next steps

Additional information and updates concerning the progress of the activiy and the forthcoming publication will be shared on this page in due course.